Business Description
Kairos Pharma Ltd
NAICS : 541713
SIC : 2833
ISIN : US48301N1046
Total Employee Number:
1Description
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. The company is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The product portfolio of the company consists of Pre-clinical or clinical-trial stage drug candidates, Therapeutic agents, and other technologies for treating diseases.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.94 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -92.9 | |||||
3-Year EPS without NRI Growth Rate | -44.2 | |||||
3-Year FCF Growth Rate | -78.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -25.5 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 57.54 | |||||
9-Day RSI | 56.16 | |||||
14-Day RSI | 52.5 | |||||
3-1 Month Momentum % | -27.18 | |||||
6-1 Month Momentum % | -43.49 | |||||
12-1 Month Momentum % | -68.42 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 11.98 | |||||
Quick Ratio | 11.98 | |||||
Cash Ratio | 9.91 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -17.5 | |||||
Shareholder Yield % | -1.98 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -98.37 | |||||
ROA % | -92.2 | |||||
ROIC % | -294.76 | |||||
3-Year ROIIC % | -399.76 | |||||
ROC (Joel Greenblatt) % | -939.2 | |||||
ROCE % | -99.47 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1.72 | |||||
Price-to-Tangible-Book | 1.72 | |||||
EV-to-EBIT | -0.86 | |||||
EV-to-Forward-EBIT | -0.62 | |||||
EV-to-EBITDA | -0.89 | |||||
EV-to-Forward-EBITDA | -0.62 | |||||
EV-to-FCF | -1.28 | |||||
| Price-to-Net-Current-Asset-Value | 2.46 | |||||
| Price-to-Net-Cash | 3.13 | |||||
Earnings Yield (Greenblatt) % | -116.28 | |||||
FCF Yield % | -48.72 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with AMEX:KAPA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Kairos Pharma Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.28 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 68.46 | ||
| 14-Day RSI | 52.5 | ||
| 14-Day ATR ($) | 0.035611 | ||
| 20-Day SMA ($) | 0.32887 | ||
| 12-1 Month Momentum % | -68.42 | ||
| 52-Week Range ($) | 0.2695 - 2.11 | ||
| Shares Outstanding (Mil) | 23.7 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Kairos Pharma Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Kairos Pharma Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 91 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | 0.36 (+5.33%) | ||
| General meeting for 2026 | 2026-06-29 12:00 | 0.35 (-7.89%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 0.49 (-8.49%) | ||
| Annual report for 2025 | 2026-03-31 | 0.55 (-8.35%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 0.79 (-3.65%) | ||
| H.C. Wainwright 27th Annual Global Investment Conference | 2025-09-08 | 1.72 (+8.86%) | ||
| Second quarter earnings results for 2025 | 2025-08-12 | 0.99 (-2.48%) | ||
| General meeting for 2025 | 2025-06-10 12:00 | 0.57 (+18.02%) | ||
| First quarter earnings results for 2025 | 2025-05-14 | 0.62 (-0.11%) |
Show
Entries
Kairos Pharma Ltd Frequently Asked Questions
What is Kairos Pharma Ltd(KAPA)'s stock price today?
The current price of KAPA is $0.34. The 52 week high of KAPA is $2.11 and 52 week low is $0.27.
When is next earnings date of Kairos Pharma Ltd(KAPA)?
The next earnings date of Kairos Pharma Ltd(KAPA) is 2026-11-13 Est..
Does Kairos Pharma Ltd(KAPA) pay dividends? If so, how much?
Kairos Pharma Ltd(KAPA) does not pay dividend.
Guru Commentaries on AMEX:KAPA
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Kairos Pharma to Participate in The Microcap Conference in January 2025 | 2024-12-16 |
Articles on Kairos Pharma Ltd
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers